Clinical Trial Detail

NCT ID NCT02460198
Title Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

colorectal cancer

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.